Home/ Stocks/ REPL

Replimune Group, Inc.

REPL XNAS

$12.06 -0.90 (-6.96%) ▼ 15-min delayed

Open

$13.00

High

$13.40

Low

$11.42

Volume

8.91M

Market Cap

$1.08B

About Replimune Group, Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 465 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2026	$0	$-313,940,000	$-3.38
FY 2026	$0	$-313,940,000	$-3.38
Q3 2026	$0	$-70,930,000	$-0.77
Q2 2026	$0	$-83,100,000	$-0.90

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for REPL yet. Check out our latest market news or earnings calendar.

Get REPL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Replimune Group, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.